Clinical perspective on innovative insulin delivery technologies in diabetes management.

Autor:	Koçkaya G; Department of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye., Battelino T; Department of Pediatric and Adolescent Endocrinology, University Medical Center Ljubljana, Ljubljana, Slovenia., Petrovski G; Sidra Medicine, Weill Cornell, Ar-Rayyan, Qatar., Jendle J; Medical Sciences, Örebro University, Örebro, Sweden., Sármán B; Department of Medicine, Faculty of Medicine Budapest Hungary, Semmelweis University, Budapest, Hungary., Elbarbary N; Department of Pediatrics, Ain Shams University, Cairo, Egypt., Gökşen D; Department of Pediatrics, Faculty of Medicine, Ege University, Bayraklı, İzmir, Türkiye., Alharbi M; Deparment of Information Secuity Operation, Ministry of Health Saudi Arabia, Riyadh, Saudi Arabia., Tibet B; Department of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye., Sharaf AM; Health Economics and Outcomes Research, ECONiX Research, Tunis, Tunisia., Ökçün S; Department of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye., Öztürk F; Department of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye., Kurnaz M; Department of Health Economics and Outcome Research, ECONiX Research, Samsun, Türkiye.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Oct 01; Vol. 15, pp. 1308319. Date of Electronic Publication: 2024 Oct 01 (Print Publication: 2024).
DOI:	10.3389/fendo.2024.1308319
Abstrakt:	Introduction: The primary objective of this study is to report the results of an online questionnaire and the in-person discussion sessions of physicians specializing in diabetes care in which their opinions about current diabetes management was obtained. Methods: The Diabetes Innovation Summit 2023 drew attendance from a diverse group of specialized physicians from multiple countries. A comprehensive literature review was conducted to examine the technologies and medical needs associated with diabetes management. Using the results of the review, a questionnaire was developed by three experts from the steering committee to solicit feedback from specialized physicians. The online survey was made accessible between 10th December 2022 and 10th January 2023. Following the online survey, six structured in-person discussion sessions were conducted with specialized physicians from the Middle East, Central-Eastern Europe, and North Africa regions. Results: The study revealed that about 59% of survey requests were answered, with many participants being pediatric endocrinologists from North Africa. Around 60% of diabetes patients followed Multiple Daily Injections (MDI) according to specialized physicians. Among MDI users, 62% employed Blood Glucose Monitors (BGM), 31% used intermittent-scanning Continuous Glucose Monitors (isCGM), and 23% used CGM. In North Africa, nearly 90% of patients used MDI due to financial constraints. While physicians focused on both Time in Range (TIR) and HbA1c for MDI-treated patients, satisfaction with TIR achieved was expressed by 31%, while 74·1% believed Real-Time CGM (rtCGM) was effective. Concerns arose about potentially misleading HbA1c results and the relatively low patient achievement of target TIR despite CGM usage. The Smart MDI System was seen favorably compared to other applications. The system's affordability was a significant barrier, particularly in the Middle East and Africa. Conclusion: The present study highlights that physicians are generally supportive of utilizing new technology. The questionnaires and the open discussion revealed the expectation that the Smart MDI technology provides better control, primarily by identifying missed boluses, while expressing concerns on the use of the technology by teenagers and children, who might forget the device and be reluctant to use in public, and by the older population, who might be challenged by the technology. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Koçkaya, Battelino, Petrovski, Jendle, Sármán, Elbarbary, Gökşen, Alharbi, Tibet, Sharaf, Ökçün, Öztürk and Kurnaz.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu